Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Syndax Pharmaceuticals (SNDX) PT Raised to $51 at Citi, Opens 90d Catalyst Watch
August 5, 2025 11:15 AM EDTCiti analyst Yigal Nochomovitz raised the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $51.00 (from $46.00) while maintaining a Buy rating.
Opens 90-Day Upside Catalyst Watch ahead of October 25 PDUFA for Revuforjs sNDA in R/R mNPM1 AML.... More